FMT may significantly improve quality of life and Parkinson Disease (PD) symptom severity measurements. We hypothesize that gut microbial dysbiosis is a major contributing factor in Parkinson's disease.

Start Date16 Oct 2024

Sponsor / Collaborator

ProgenaBiome LLCStartup

NCT04630847

/ Not yet recruitingPhase 1

An Open-Label Phase I Trial of Vancomycin Followed by Familial Fecal Microbiota Transplant in Minor and Adult Subjects With Autism Spectrum Disorder (ASD) for Treatment of Social Deficits and Language Delays.

This is an open-label clinical trial to evaluate the benefits of familial fecal microbiota transplant following a 6-week treatment with Vancomycin in minor and adult subjects with ASD for treatment of social deficits and language delays.

Start Date01 May 2022

Sponsor / Collaborator

ProgenaBiome LLCStartup

NCT04949230

/ CompletedNot Applicable

A Retrospective Study to Analyze Efficacy of COVID-19 Treatments

Surveys administered to subjects who have recovered from COVID-19 to assess how effective their treatment was.

Start Date19 Feb 2021

Sponsor / Collaborator

ProgenaBiome LLCStartup

100 Clinical Results associated with ProgenaBiome LLC

0 Patents (Medical) associated with ProgenaBiome LLC

Literatures (Medical) associated with ProgenaBiome LLC

01 Nov 2022·Future Microbiology

Letter in Reply: More Power To Ivermectin Multidrug Therapy

Letter

Author: McCullough, Peter A ; Dave, Sonya ; Hazan, Sabine ; Borody, Thomas J

A review Many thanks for your review ofour observational study report of patients who'did not qualify' for the. Randomized.Trial referenced by the NCT.These patients were treated along the lines of the rapidly evolving community. Standard of care for high-risk patients COVID-19. Age is an important risk-stratifier and our sample included 47, 46, 46 and 43 yr olds individuals but in addition five notable patients were 94, 86, 92, 87 and 86 years of age, far away from a threshold of 50. All of these elderly patients survived. We are familiar with the extraordinary circumstances surrounding publication of COVID-19 treatments and vaccine safety, and thus we rely on the data available irresp. of post-publication actions taken by journals and publishers.Our study was by no means limited to recovered patients. We note two patients died, who refused (yet were offered) the treatment component of our study .Inclusion criteria were as follows: positve PCR for COVID-19, informed consent, age ≥18 years old and agreement to practice two highly effective methods of birth control if of childbearing potential. Exclusion criteria were allergies or drug interactions with the combination therapy omponents; listed comorbidities, including seizure risk; and pregnancy.One should note that the underlying condition criteria information available in this database refers to chronic conditions of any type, whether or not the condition induces COVID-19 vulnerability. With this definition, 100% of control subjects and Ivermectin Combination Therapy treated subjects had underlying conditions of any type.Fortunately, with the drugs readily available, used in a sequenced combination, the vast majority of hospitalizations and deaths can be avoided for those who develop COVID-19 illness, irre997spective of their prior vaccination status.We encourage correspondents and the readership to take a pos. stance on early therapeutics as it is the only strategy to reduce the risk of hospitalization and death in COVID-19, particularly in the bourgeoning numbers of individuals who have been fully vaccinated and now have serious breakthrough infection.

SARS-CoV-2 as a Trigger in the Development of Tourette’s-Like Symptoms: A Case Report

Author: Jordan, Sheldon ; Hazan, Sabine

AbstractBackground: Reports have been surfacing surrounding CNS-associated symptoms in individuals affected by coronavirus disease 19 (COVID-19). Tourette syndrome is a neuropsychiatric disorder with usual onset in childhood. Gut microbiota can affect central physiology and function via the microbiota-gut-brain axis. The authors of this case report describe Tourette’s-like symptoms in a patient resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection disrupting gut microbiota. Case Presentation: This case involves a 16-year-old female that developed acute onset Tourette’s-like symptoms along with neuropsychiatric symptoms after exposure to and infection from SARS-CoV-2. The patient had negative nasopharyngeal (NP) real-time reverse transcription-PCR (RT-PCR) tests for SARS-CoV-2 on five occasions from August of 2020 through June of 2021. The patient’s symptoms continued to worsen over the next six months until next-generation sequencing (NGS) revealed SARS-CoV-2 in her stool. Her treatment was adjusted as NGS revealed SARS-CoV-2 in her stool. Repair of the gastrointestinal microbiota, treatment with nutraceutical and pharmaceutical agents, as well as alterations in her surroundings resulted in dramatic improvement in the microbiome and a significant reduction of symptoms.Discussion: The use of (RT-PCR) testing to determine the presence or absence of SARS-CoV-2 may be inadequate and inaccurate for individuals that have been exposed to the virus. In addition, the impact of SARS-CoV-2 infection of the GI tract may cause significant havoc in the gut microbiota. Additional testing, eradication of infectious agents, as well as restoration of the gut microbiome are needed to effectively manage and treat this condition. The patient’s symptoms worsened over the next six months until next-generation sequencing (NGS) revealed SARS-CoV-2 in her stool and her treatment was adjusted. Treatment with nutraceuticals and alterations in her surroundings was followed by a more normal microbiome and a dramatic reduction in symptoms.

SARS-CoV-2 as a Trigger in the Development of Tourette’s-Like Symptoms: A Case Report

Author: Hazan, Sabine ; Nowicki, ND John ; Jordan, Sheldon

AbstractBackground: Reports have been surfacing surrounding CNS-associated symptoms in individuals affected by coronavirus disease 19 (COVID-19). Tourette syndrome is a neuropsychiatric disorder with usual onset in childhood. Gut microbiota can affect central physiology and function via the microbiota-gut-brain axis. The authors of this case report describe Tourette’s-like symptoms in a patient resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection disrupting gut microbiota. Case Presentation: This case involves a 16-year-old female that developed acute onset Tourette’s-like symptoms along with neuropsychiatric symptoms after exposure to and infection from SARS-CoV-2. The patient had negative nasopharyngeal (NP) real-time reverse transcription-PCR (RT-PCR) tests for SARS-CoV-2 on five occasions from August of 2020 through June of 2021. The patient’s symptoms continued to worsen over the next six months until next-generation sequencing (NGS) revealed SARS-CoV-2 in her stool. Repair of the gastrointestinal microbiota, treatment with nutraceutical and pharmaceutical agents, as well as alterations in her surroundings resulted in dramatic improvement in the microbiome and a significant reduction of symptoms.Discussion: The use of RT-PCR testing to determine the presence or absence of SARS-CoV-2 may be inadequate and inaccurate for individuals that have been exposed to the virus. In addition, the impact of SARS-CoV-2 infection to the GI tract may cause significant havoc in the gut microbiota which may lead to disruption of the blood brain barrier, disruption to the gut- microbiome-brain axis, and neurological symptoms. Additional testing, eradication of infectious agents, as well as restoration of the gut microbiome are needed to effectively manage and treat this condition.

News (Medical) associated with ProgenaBiome LLC

07 Dec 2023

·www.prnewswire.com

ProgenaBiome Given Presidential Award at ACG Conference for Microbiome Research

VENTURA, Calif., Dec. 7, 2023 /PRNewswire/ -- Last month, ProgenaBiome™, a genetic research lab dedicated to studying and understanding the the microbiome, received yet another presidential award from the American College of Gastroenterology (ACG) at the ACG Annual Scientific Meeting in Vancouver. This marks their fourth year of attendance at the conference and third consecutive year of presidential-level recognition for research on the microbiome. Continue Reading Photo courtesy of Dr. Sabine Hazan from the ACG Conference in Vancouver, Canada. Dr. Sabine Hazan with ProgenaBiome's submitted abstracts at the 2023 ACG Conference in Vancouver, Canada. The ACG conference brings GI physicians and researchers from around the world to discuss the latest clinical information in gastroenterology and hepatology. According to ACG, each year less than 5% of accepted abstracts are awarded the presidential distinction for "high quality, novel, unique, and interesting research." ProgenaBiome was given the award for their research on commercial Probiotic products. Their groundbreaking findings indicated significant discrepancies between probiotic food label claims and their contents. More specifically, only five out of 25 tested commercially available products with label-promised Bifidobacteria – an organism essential for a healthy microbiome – truly contained the bacteria. Dr. Sabine Hazan, world-renowned gastroenterologist, and founder of ProgenaBiome, explained that this research raises an important, though disheartening, fact about the commercial health industry. "The abstract on probiotics shows the need for quality testing of health products by an independent party. But more importantly, it shows that there is marketing and influencing that exists to mislead consumers," said Hazan. In addition to this research, ProgenaBiome submitted 3 abstracts which present cutting edge research that could majorly alter understanding and treatment of the microbiome. The second abstract introduced the findings that support the concept of an individualized microbiome, meaning gut bacteria varies by individual. This research suggests a complex interplay of host-specific factors that play a role in microbiome diversity. The third abstract defied the narrative on Ivermectin, showing that Ivermectin has a role on the microbiome short-term. Which could benefit investigators using it for various therapeutic interventions. Hazan believes that in this growing industry, ProgenaBiome's authentic microbiome research is the "key to science," even if met with controversy. Hazan noticed a growing number of articles have been retracted in the last four years. "This goes against the essence of science. Science is about controversy and defying the narrative. Science is about 'prove me wrong.' Retraction of research should never occur for this reason," said Hazan. The fourth abstract ProgenaBiome submitted describes "significant microbiome changes" in patients suffering from Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) following treatment with Bovine IgG. These findings suggest that Bovine IgG may influence essential gut bacteria – specifically Alisteps, Bacteroides, Bifidobacteria, Actinobacteria, Bacteroidetes and Proteobacteria – to help manage IBS and IBD symptoms. These abstracts are the result of ProgenaBiome's community of specialized physicians who explore topics that others in the medical community see as too daunting or controversial to study. "We do the research nobody wants to do because of expense and controversial nature, but it is research everyone wants to know. Anything short of challenging the narrative is not science – it's propaganda," said Hazan. ProgenaBiome is a standalone research company that is not backed by a large pharmaceutical corporation, but it is interested in guiding the pharmaceutical industry towards this new frontier of research. Their research is funded by individual donations and proceeds from sales products "Lets Talk Sh!T" book and Biomeboosters. "We cannot do this without support from our community, so please consider donating before the end of the year to the Microbiome Research Foundation ," said Hazan. Read more about ProgenaBiome's research, mission, and register to the newsletter through their webpage, progenabiome.com. For more timely information, follow Dr. Hazan on X @SabinehazanMD and Instagram @dr.sabinehazan. For more, visit: Media Contact: 800-380-7764 [email protected] Author: Jamie Miller [email protected] 404-422-9433 SOURCE ProgenaBiome

Microbial therapy

100 Deals associated with ProgenaBiome LLC

100 Translational Medicine associated with ProgenaBiome LLC

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 03 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Fecal Microbiota(ProgenaBiome)	Autistic Disorder More	Phase 1

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis